These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 524858)

  • 1. [Influenza virus neuraminidase and its role in anti-influenzal immunity].
    Isaeva EI; Platonova AL; Rovnova ZI; Kosiakov PN
    Vopr Virusol; 1979; (6):615-9. PubMed ID: 524858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenic activity of the influenza virus dependent on ne uraminidase (author's transl)].
    Isaeva EI; Rovnova AI; Kosiakov PN
    Vopr Virusol; 1975; (5):525-8. PubMed ID: 1210315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.
    Johansson BE; Kilbourne ED
    J Infect Dis; 1990 Oct; 162(4):800-9. PubMed ID: 2401790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protection in mice after immunization with H2N2, H3N2, and Heq2Neq2 influenza virus strains.
    Anker WJ; Bakker AK; Masurel N
    Infect Immun; 1978 Jul; 21(1):96-101. PubMed ID: 711325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice.
    Babai I; Samira S; Barenholz Y; Zakay-Rones Z; Kedar E
    Vaccine; 1999 Mar; 17(9-10):1223-38. PubMed ID: 10195636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
    Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR
    J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cross protection in mice immunized with different anti-influenza preparations].
    Rudenko LG; Sosunov AV; Zykov MP
    Vopr Virusol; 1981; (6):706-9. PubMed ID: 7336695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunogenic activity of the viral hemagglutinin and neuraminidase from live and inactivated influenza vaccines].
    Kustikova IuG; Gagarinova VM; Gorev NE; Shadrin AS
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Apr; (4):79-84. PubMed ID: 6868890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model.
    Mishin VP; Nedyalkova MS; Hayden FG; Gubareva LV
    Vaccine; 2005 Apr; 23(22):2922-7. PubMed ID: 15780741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live bivalent vaccine for parainfluenza and influenza virus infections.
    Maeda Y; Hatta M; Takada A; Watanabe T; Goto H; Neumann G; Kawaoka Y
    J Virol; 2005 Jun; 79(11):6674-9. PubMed ID: 15890905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice.
    Johansson BE; Grajower B; Kilbourne ED
    Vaccine; 1993; 11(10):1037-9. PubMed ID: 8212824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neuraminidase on potency of inactivated influenza virus vaccines in mice.
    Reichert E; Mauler R
    Dev Biol Stand; 1975; 28():319-23. PubMed ID: 1126575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural infection with influenza A (H3N2). The development, persistance and effect of antibodies to the surface antigens.
    Smith AJ; Davies JR
    J Hyg (Lond); 1976 Oct; 77(2):271-82. PubMed ID: 185291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.